A novel glycosyltransferase-related lncRNA signature correlates with lung adenocarcinoma prognosis

Chengyu Bian; Xinti Sun; Jingjing Huang; Wenhao Zhang; Guang Mu; Ke Wei; Liang Chen; Yang Xia; Jun Wang

doi:10.3389/fonc.2022.950783

A novel glycosyltransferase-related lncRNA signature correlates with lung adenocarcinoma prognosis

Front Oncol. 2022 Aug 18:12:950783. doi: 10.3389/fonc.2022.950783. eCollection 2022.

Authors

Chengyu Bian¹, Xinti Sun², Jingjing Huang¹, Wenhao Zhang¹, Guang Mu¹, Ke Wei¹, Liang Chen¹, Yang Xia¹, Jun Wang¹

Affiliations

¹ Department of Thoracic Surgery, Jiangsu Province People's Hospital and the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
² Department of Thoracic Surgery, Tianjin Medical University General Hospital, Tianjin, China.

Abstract

Background: Lung adenocarcinoma (LUAD) is one of the most fatal cancers in the world. Previous studies have shown the increase in glycosylation level, and abnormal expressions of related enzymes are closely related to various cancers. Long non-coding RNAs (lncRNAs) play an important role in the proliferation, metabolism, and migration of cancer cells, but the underlying role of glycosyltransferase (GT)-related lncRNAs in LUAD remains to be elucidated.

Methods: We abstracted 14,056 lncRNAs from The Cancer Genome Atlas (TCGA) dataset and 257 GT-related genes from the Gene Set Enrichment Analysis (GSEA) database. Univariate, LASSO-penalized, and multivariate Cox regression analyses were conducted to construct a GT-related lncRNA prognosis model.

Results: A total of 2,726 GT-related lncRNAs were identified through Pearson's correlation analysis, and eight of them were utilized to construct a GT-related lncRNA model. The overall survival (OS) of the low-risk group continued to be superior to that of the high-risk group according to the subgroups classified by clinical features. The risk model was proved to have independent prognostic characteristics for LUAD by univariate and multivariate Cox regression analyses. The status of the tumor immune microenvironment and the relevant immunotherapy response was significantly different between the two risk groups. The candidate drugs aimed at LUAD subtype differentiation were identified.

Conclusion: We constructed a risk model comprising eight GT-related lncRNAs which was identified as an independent predictor of prognoses to predict patient survival and guide-related treatments for patients with LUAD.

Keywords: Lung adenocarcinoma; biomarker; glycosyltransferase; lncRNA; prognosis.